In the latest trading session, 0.58 million Spruce Biosciences Inc (NASDAQ:SPRB) shares changed hands as the company’s beta touched 2.36. With the company’s most recent per share price at $0.38 changing hands around $0.0 or 0.97% at last look, the market valuation stands at $15.84M. SPRB’s current price is a discount, trading about -1465.79% off its 52-week high of $5.95. The share price had its 52-week low at $0.34, which suggests the last value was 10.53% up since then. When we look at Spruce Biosciences Inc’s average trading volume, we note the 10-day average is 0.26 million shares, with the 3-month average coming to 563.22K.
Analysts gave the Spruce Biosciences Inc (SPRB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SPRB as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Spruce Biosciences Inc’s EPS for the current quarter is expected to be -0.2.
Spruce Biosciences Inc (NASDAQ:SPRB) trade information
Instantly SPRB is in green as seen in intraday trades today. With action 1.03%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -8.69%, with the 5-day performance at 1.03% in the green. However, in the 30-day time frame, Spruce Biosciences Inc (NASDAQ:SPRB) is -8.56% down. Looking at the short shares, we see there were 0.44 million shares sold at short interest cover period of 0.73 days.
Spruce Biosciences Inc (SPRB) estimates and forecasts
Data shows that the Spruce Biosciences Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -21.01% over the past 6 months, a 19.35% in annual growth rate that is considerably higher than the industry average of 15.90%. Year-over-year growth is forecast to reach -49.52% down from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 885k. 4 analysts are of the opinion that Spruce Biosciences Inc’s revenue for the current quarter will be 500k. The company’s revenue for the corresponding quarters a year ago was 2.89M and 2M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -69.35%. The estimates for the next quarter sales put growth at -75.02%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -22.95%. The 2025 estimates are for Spruce Biosciences Inc earnings to increase by 24.68%, but the outlook for the next 5-year period is at 20.77% per year.
SPRB Dividends
Spruce Biosciences Inc is expected to release its next quarterly earnings report in March.
Spruce Biosciences Inc (NASDAQ:SPRB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 12.00% of Spruce Biosciences Inc shares while 42.41% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 48.19%. There are 42.41% institutions holding the Spruce Biosciences Inc stock share, with RIVERVEST VENTURE MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 7.1449% of the shares, roughly 2.94 million SPRB shares worth $1.52 million.
CARLYLE GROUP INC. holds the second largest percentage of outstanding shares, with 7.0481% or 2.9 million shares worth $1.52 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 638.56 shares estimated at $0.24 million under it, the former controlled 1.55% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.48% of the shares, roughly 197.19 shares worth around $75187.0.
